Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Hinge Health Inc. Class A Common Stock (HNGE) vs Icl Group Ltd (ICL) Price & Performance

Hinge Health Inc. Class A Common StockTrade
Icl Group LtdTrade

Price performance (Past 24H)

Key statistics

Hinge Health Inc. Class A Common Stock vs Icl Group Ltd — how do they compare? Hinge Health Inc. Class A Common Stock trades at $104.95 (market cap $8.48B), while Icl Group Ltd trades at $4.99 (market cap $6.38B). The key difference: Hinge Health Inc. Class A Common Stock is the larger of the two by market cap, and Icl Group Ltd pays a 4.13% dividend while Hinge Health Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Hinge Health Inc. Class A Common Stock for 0 Days and Icl Group Ltd for 56 Days on average.

HNGEICL
Market Cap
$8.48B$6.38B
Volume
879,7991,104,238
Sector
HealthBasic Materials
52-Week High
$105.14$6.80
52-Week Low
$31.17$4.80
Typical Hold Time
0 Days56 Days
Enterprise Value
$8.10B$9.02B
Dividend Yield
—4.13%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Hinge Health Inc. Class A Common Stock

Hinge Health (HNGE) trades at $105.14, up 0.31% on the day and near its 52-week high. The stock shows strong analyst support with a 93.75% buy rating, though the current price exceeds the consensus target of $101.62. Recent earnings beat expectations in two of the last three quarters, with Q3 2026 results due November 2. Fundamentals indicate robust revenue growth projections from $588 million in 2025 to $720 million in 2026, alongside a shift to profitability, but valuation multiples like EV/EBITDA at 82.33 remain elevated.

The outlook is cautiously optimistic given projected profitability and expansion into migraine and GI care, but risks include high insider selling, competitive pressures, and the stock's premium valuation. Execution on growth targets and Q3 earnings will be critical for sustaining momentum.

Icl Group Ltd

ICL trades at $4.99, up 1.01% today, with a bearish technical signal from moving averages. The company reported Q2 2026 EPS of $0.12, beating expectations, and maintains a dividend of $0.06. Revenue for 2025 was $7.15B with a net income margin of 3.95%. Valuation metrics show a P/E of 20.75 and P/B of 1.05, while analyst consensus is a Hold with a $6.08 price target.

ICL faces headwinds from fertilizer industry challenges but shows earnings resilience. The stock offers a moderate upside to the consensus target, supported by cost-transformation plans. Risks include input cost pressures and competitive dynamics. Institutional interest is evident with Amundi increasing its stake by 49.7% in Q1 2026.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

HNGE
100% Buy0% Sell
Avg holding period · 0 Days
ICL
100% Buy0% Sell
Avg holding period · 56 Days

About Hinge Health Inc. Class A Common Stock

Hinge Health Inc. operates a digital musculoskeletal (MSK) care platform that delivers exercise therapy for joint and muscle conditions through health plans and employers. Its Precision Motion Technology combines wearable sensors and computer vision to guide patients through clinician-directed physical therapy remotely.

Read more on HNGE →

About Icl Group Ltd

ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.

Read more on ICL →